Therefore, it is expected that subjects with frequent or enhanced CYP2D6 activity could be subjected to equally the substrate drug 5-MeO-DMT plus the Lively metabolite bufotenine, and thus might need additional intricate drug results [37]. End users report encountering intricate and vivid visual